Analysts have clear opinions on CNST.

There are 6 analysts on the Wall offering 12 month price targets for Constellation Pharmaceuticals in the last 3 months. The average price target is $50.00 with a high forecast of $65.00 and a low forecast of $40.00. The average price target represents a 30.55% increase from the last price of $38.30.
Constellation Pharmaceuticals, Inc. (CNST) is followed by 6 analysts on the street.

Do Kim from BMO Capital rates it a Hold with a target of $42.00.

Similarly, Last month Andrew Fein of H.C. Wainwright Reiterated a Buy with a target of $50.00.

The consensus on the street is Strong Buy.

What does Constellation Pharmaceuticals, Inc.(CNST) do ?
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.

Constellation Pharmaceuticals, Inc. (CNST) Insider Trades

Multiple company employees have indulged in significant insider trading. Constellation Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, Evnin Anthony B : P – Purchase(+$13,800,000) of CNST in the trading session of 2019-12-13.

10% Venrock Healthcare Capital Partners Iii, L.P. : P – Purchase(+$13,800,000) of CNST in the trading session of 2019-12-13.

10% Regents of the University of California : S – Sale(-$5,706,635) of Constellation Pharmaceuticals, Inc. in the trading session of 2019-11-08.